Dr. Bo Liang is a serial entrepreneur with over 20 years of experience in drug discovery research, chemical and material sciences, biotechnology and materials venture and management. Dr. Liang is Co-Founder, Chairman and CEO of IVIEW Therapeutics Inc. a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We invest in novel mechanisms of action, and drug delivery technology platforms that allow us to bring forward differentiated assets with potentially superior target product profiles. The company's innovative product pipeline spans over dry eye, acute conjunctivitis, myopia, presbyopia and novel ocular gene therapies. Lead programs to treat dry eye and acute conjunctivitis are in phase II clinical trials for late-stage development. Dr. Liang was also co-founder and Chairman of Adesso Advanced Materials, which developed revolutionary degradable curing agents and recyclable epoxy resin systems for next-generation sustainable carbon fiber composites. Dr. Liang co-founded CLS Pharmaceuticals in New York city with ophthalmologists in 2006, and advanced an ophthalmic drug project into clinical phase II stage to treat viral conjunctivitis and then co-founded Foresight Biotherapeutics, Inc. with a New York venture capital firm to advance the program. The program was acquired by Shire Pharmaceuticals in 2015 after completion of successful phase II trials. Soon after his exit from the first venture, he co-founded IVIEW Therapeutics Inc. Dr. Liang was previously Senior Scientist at Pharmacopeia, Inc. in New Jersey for six years, leading medicinal chemistry development of first-in-class small molecule therapeutics for respiratory and CNS diseases. Dr. Liang holds over 50 issued international patents and patent applications. He was a reviewer for Journal of Bioorganic and Medicinal Chemistry. Dr. Liang is Co-Founder of Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) and served as the first President of SAPA-GP from 2002 to 2004. Dr. Liang obtained his PhD in chemistry from the University of Pennsylvania, MBA from the Stern School of Business of NYU, and Bachelor of chemistry from Peking University in China.

Dr. Hemmati is a fellowship trained cornea specialist and has co-founded and served as CMO of two venture-backed ophthalmic pharmaceutical companies, Optigo Bio (retina; long acting anti-VEGF) and Levation Pharma (oculoplastics; drug for acquired blepharoptosis). He has served CMOs of both Vyluma (pediatric myopia; present) and Stargazer Pharma (Stargardt disease; recent). Dr. Hemmati joined IVIEW Therapeutics' Board of Directors as a Board member since January 2025, and he has advised IVIEW and head IVIEW's clinical development as Chief Medical Advisor since May 2023. Previously, Dr. Hemmati was Vice President of New Therapies at Capricor Therapeutics, where he led development of the company’s exosome platform for inflammatory diseases of the eye, skin, and gastrointestinal tract. He also served as Director, Clinical Development at Allergan, where he helped design and run early to late-stage clinical trials in the Ophthalmology Therapeutic Area. Dr. Hemmati is a consultant to numerous ophthalmology biotech and pharmaceutical companies developing treatments for anterior and posterior segment diseases, including rare inherited retinal diseases such as Retinitis Pigmentosa and Stargardt Disease. He is a board-certified, licensed ophthalmologist in active academic clinical practice in Los Angeles and continues to publish articles on clinical treatment guidelines and ophthalmic pharmaceutical pricing. Dr. Hemmati holds a BS in Biological Sciences from Stanford University. He received his MD from UCLA and PhD in Biology from Caltech University in the Medical Scientist Training Program. He completed an internship in Internal Medicine at Stanford Hospital, an ophthalmology residency at the Wilmer Eye Institute at Johns Hopkins Hospital, a post-doctoral fellowship in Chemical Engineering with Dr. Robert Langer at MIT, and a clinical fellowship in ophthalmology at the Massachusetts Eye & Ear Infirmary at Harvard Medical School.

Dr. Hany Michail is Chief Strategy Advisor with IVIEW. He is an Ophthalmologist, MIT trained engineer, and Industry professional with extensive educational background and experience. Dr. Michail started his academic training in biomedical engineering with a BS from the Massachusetts Institute of Technology, followed by an MD and PhD from Rutgers University. He completed his Ophthalmology clinical training at the Washington University in St Louis. In addition to practicing ophthalmology, Dr. Michail has held academic and senior corporate positions in the medical device and pharmaceutical industries and has led product development across multiple therapeutic areas. Previous industry experience includes Alcon, Novartis, SUN, and SPARC amongst others. ​

With over 30 years of hands-on and managerial experience in the pharmaceutical industry, Zuliang has previously spent over 18 years developing his professional career with Merck & Co. Inc. Zuliang has been involved with the market launch of numerous drugs including Januvia® (sitagliptin), Janumet®, Zetia® (ezetimibe) and Vytorin®, quickly excelling in his field to become a subject matter expert in DMPK, pharmacology, safety assessment, and translational medicine in various therapeutic areas. Zuliang holds extensive novel drug R&D experience in CRO, biotech, and biopharma with a track record of success developing drug candidates both clinically and pre-clinically. Zuliang has proved excellent leadership in a diverse and cross-functional team environment. Zuliang holds a M.D. from JiaoTong University Medical School in China, and later practiced as a urology surgeon at RuiJin Hospital in Shanghai, China. Zuliang also received his M.S. in Molecular Biology from Montclair State University, NJ.

Wei Wang is a Board Director and Vice President of Translational Research of IVIEW Therapeutics Inc. She also serves as Head of Operations at the company. Wei focuses on preclinical pharmacology and toxicology and leads due diligence in business development. As the Operation head, she also oversees HR and accounting team. Prior to joining IVIEW, Wei was Principal Scientist at Colgate-Palmolive Global Technology Center. During her 12 years there she was mainly focusing on preclinical research on oral care product development. She led identification and assessment of new active and functioning ingredients, developed novel in vitro models and identified new biomarkers. Wei proposed and established research programs of two new indications. She also prepared clinical protocols and executed four clinical studies. Wei holds over 10 issued patents and patent applications, published 15 research articles and a book chapter. She was NIH Kirschstain NRSA Postdoctoral Fellow at Fox Chase Cancer Center. Wei obtained M.S. and Ph.D. in chemistry from the University of Pennsylvania, and B.S. in chemistry from Peking University, China.

Bin Hu Karg is a seasoned corporate and technology transactions attorney with over a decade of experience advising C-suite executives and clients on high-stakes transactions in the biotech and life sciences industries. Combining extensive legal expertise with deep industry knowledge, she also excels as a strategic business development leader, helping companies identify growth opportunities and forge successful partnerships. In her work, Bin blends legal acumen with a business-driven approach, honed over years of advising technology and growth enterprises from inception to successful exits, including IPOs and mergers and acquisitions. Her areas of expertise include fundraising, corporate governance, capital markets, and strategic and commercial collaborations, enabling her to guide companies through pivotal milestones and develop strategies for long-term success. Throughout her career, Bin has built a strong track record in cross-border transactions and global market strategies. Her ability to align legal frameworks with business goals has established her as a trusted advisor to executives and investors in the biotech and life sciences sectors. Earlier in her career, Bin worked at premier international law firms, including Davis Polk & Wardwell LLP and Wilson Sonsini Goodrich & Rosati, where she advised on high-profile capital markets transactions, venture financings, and mergers and acquisitions. In addition to her role at IVIEW, she serves as a partner at VCL Law, where she continues to advise a range of technology and growth enterprises. Bin holds a Juris Doctor from Columbia Law School, where she was recognized as a Harlan Fiske Scholar, and an LLM from New York University School of Law. Fluent in English and Chinese, with conversational proficiency in German, she brings a global perspective to her work in the biotech and life sciences industries.

Dr. Short is an accomplished nonclinical drug development expert with 35 years of experience in the pharmaceutical industry, including small molecules, biologics, oligonucleotides, and gene and cell therapy. Previously he was at Allergan as Sr Director of Toxicology and Sr. Director of Pathology and held positions at GlaxoSmithKline (formerly SmithKline Beecham). Dr Short a highly skilled toxicologist, board-certified veterinary pathologist and a recognized expert in ocular drug and device development. Since 2016 he has consulted for over 140 ocular drug projects including extensive experience in designing and implementing nonclinical development plans, including pharmacology, pharmacokinetic and toxicology studies supporting R&D portfolios. Dr Short provides adroit integration and interpretation of clinical and anatomic pathology data within toxicology reports including pathology peer reviews. He is an author and reviewer of regulatory and clinical documents with numerous FDA regulatory meetings and/or Pre-IND, IND, Type C, End-of-Phase 2 and NDA submissions per year and extensive experience with approved drugs for ocular (Durysta®, Restasis®, Ozurdex®, Lumigan®, Alphagan®, Trivaris®, Refresh/Optive®, Inveltys® and Eysuvis®), dermatologic (Rhofade®, Tazorac®, and Aczone®), neurologic and urologic (BOTOX®) and cardiovascular (Giapreza®) indications. Dr. Short has a DVM from University of California, Davis, a PhD in Experimental Pathology from University of North Carolina, Chapel Hill. Location: Laguna Beach, CA, USA

Gary D. Novack, Ph.D. is a clinical pharmacologist specializing in ophthalmology. He was educated at several UC campuses (BA UC Santa Cruz, PhD UC Davis, and neurophysiology fellowship at UCLA). He began his career as a researcher at pharmaceutical firms, and then in 1989 founded PharmaLogic Development, Inc. , a consultancy providing R&D services to medical device and biopharmaceutical firms. He has contributed to over 60 approved/cleared products and authored over 350 peer-reviewed papers. Dr. Novack is a Professor of Ophthalmology & Vision Science at UC Davis, a UC Regent Emeritus (where he chaired the Audit Committee), and past president of the UC Santa Cruz Alumni Association and its Foundation. He was a founding member of editorial board of The Ocular Surface, and is also on the editorial board of the Journal of Ocular Pharmacology and Therapeutics, and Eye & Contact Lens. Dr. Novack is a Fellow of the American College of Clinical Pharmacology and a Diplomate of the American Board of Clinical Pharmacology. The AAO awarded him the Achievement Award and also the Secretariat Award for Special Contributions. He received ARVO's Roger Vogel award for pharmaceutical research.

Bringing over 30 years of expertise in clinical operations, Jeanette is an affable seasoned professional who manages ophthalmic clinical operations and oversees trials across all stages of development. As the co-founder and CEO of PRN Pharmaceutical Research Network, LLC, a leading clinical research organization specializing in ophthalmic research, she has been a driving force behind the company's achievements. Before PRN's inception, Jeanette specialized in coordinating ophthalmic clinical trials and founded two SMOs. Under her leadership at PRN, she has effectively managed more than 70 research projects spanning the United States, Australia, Canada, and Europe. Leveraging her profound knowledge of ophthalmology, Jeanette has played a key role in advising strategic and operational leaders, training Site and Project Managers, Clinical Trial Associates, and Clinical Trial Coordinators. Beyond her managerial contributions, Jeanette is a critical care experienced Registered Nurse who has authored over 100 scientific articles focusing on ophthalmic treatments and research processes. Her expertise has been showcased through presentations at scientific meetings and as an invited lecturer.

Dr. Yali Sun has 30 years of pharmaceutical industry experience in drug development with extensive experience in all phases of analytical development for both drug substance (DS) and drug product (DP) development. Dr. Sun joined IVIEW Therapeutics as a CMC consultant since 2023 and currently serves as CMC Analytical Head to oversee both DS and DP development activities for IVIEW’s small molecule drug development programs. Previously, she worked as Director in Analytical Development at Celgene Corporation for 17 years, then as Director of Analytical Strategy and Operations for 2 years after Celgene was acquired by BMS in 2019. At Celgene, she served as a CMCDT/analytical project lead in several pharmaceutical project development teams (PDT) and provided guidance for API and drug product development. She also authored and reviewed CMC sections (Module 3) of IND/NDA and provided responses to HA's requests for numerous development and commercial products. She made significant contributions to Celgene's marketed products, Revlimid® and Otezla® from discovery to commercialization. Dr. Sun obtained her Ph.D. in Organic Chemistry from the University of Akron, M.S. in Medicinal Chemistry from Institute of Materia Medica, Chinese Academy of Medical Science and B.S. in chemistry from Peking University in China.

Clinical Professor, Director Of Cornea, Cataract, And Refractive Surgery At The Galvin Herbert Eye Institute, UC Irvine Dr. Marjan Farid is board-certified UCI Health ophthalmologist who specializes in cornea, cataract and refractive surgery, and the treatment of ocular surface disorders. She performs all types of corneal transplants, including femtosecond laser-enabled lamellar keratoplasty. She also performs limbal stem cell transplants and artificial corneal transplants to treat severe ocular surface disorders. Farid earned her medical degree at UC San Diego, followed by an internship at Scripps Mercy Hospital in San Diego. She completed a residency in ophthalmology at the UCI School of Medicine, where she also received fellowship training in cornea and external disease under the late Dr. Roger Steinert, an international pioneer in refractive laser surgery. Her research focus is on corneal surgery and the use of the femtosecond laser in corneal transplantation. Her work has appeared in many peer-reviewed journals.

Pedram Hamrah, M.D., FACS, FARVO, is a leading authority on corneal and ocular surface diseases, with a special focus on neuro-immune interactions, neuropathic corneal pain, and dry eye disease. He serves as Professor and Vice Chair of Academic Medicine in Ophthalmology at the University of South Florida (USF) Dr. Hamrah’s research has advanced the understanding of the corneal immune system, particularly the role of antigen-presenting cells in corneal transplantation, inflammation, and infection. His work has also illuminated how immune and nervous system interactions contribute to ocular surface disorders, helping to define new pathways of disease. He has pioneered the use of in vivo confocal microscopy for the study of corneal nerves and immune cells, significantly enhancing clinicians’ ability to diagnose and monitor neuropathic corneal pain and related conditions. His studies have provided critical insights into mechanisms underlying persistent ocular pain and have opened new avenues for diagnostic imaging and targeted therapy. In addition to his research, Dr. Hamrah is an internationally recognized educator and clinician. He has published extensively in leading ophthalmology and immunology journals and has lectured around the world on corneal immunology, ocular surface disease, and neuropathic pain. Dr. Hamrah’s leadership and scientific contributions have been recognized by numerous awards, and he is a Fellow of both the American College of Surgeons (FACS) and the Association for Research in Vision and Ophthalmology (FARVO).

David Wirta, M.D., founded his practice 20 years ago with the highest level of ophthalmology experience and quality care in mind. Since then he has built his practice with optimal results and patient satisfaction. He has grown his practice through referrals from his satisfied patients and respected colleagues in the Orange County medical community. Dr. David Wirta is a specialist in cosmetic eyelid surgery, eyelid and tear duct plastic and reconstructive surgery, as well as medical diseases of the eye. After graduating with honors from UCLA medical school, he completed a surgical and medical internship at Harbor-UCLA Medical Center. He then completed a three-year residency in ophthalmology at the prestigious Jules Stein Eye Institute at UCLA. Dr. Wirta then attained exclusive status as Fellow in Ophthalmic Plastic and Reconstructive Surgery. As a specialist in cosmetic surgery of the eyelids and upper face, including endoscopic forehead lifts, Dr. Wirta has positioned himself as a community expert in the field. He is accomplished in surgical reconstruction of the delicate ocular tissues. He has expertise in Botox injections for facial wrinkles as a result of his 17 years of experience. In 1998, Dr. Wirta founded the Eye Research Foundation, the West Coast’s premier center for pharmaceutical eye research. The foundation conducts clinical studies on glaucoma, blepharitis, eye allergy, dry eye and other eye conditions, and provides important data to the medical community. Each year, many promising eye treatments are tested under the direct supervision of Dr. David Wirta.

Donald L. Budenz, MD, MPH, received his medical degree from Harvard Medical School, USA. He completed an ophthalmology residency at the University of Pennsylvania, Scheie Eye Institute, USA. Dr Budenz then completed a Heed Foundation Fellowship in glaucoma at the Bascom Palmer Eye Institute, University of Miami School of Medicine, USA, where he subsequently was a faculty member for 17 years. In 2004, he received a Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health. He is currently the Kittner Distinguished Professor and Chairman of Ophthalmology at the University of North Carolina, Chapel Hill, USA and Past President of the American Glaucoma Society. Dr Budenz is an editorial reviewer for numerous medical journals, is on the Editorial Board of the American Journal of Ophthalmology and the Journal of Glaucoma, as well as serving as the Editor in Chief of the Glaucoma issue of Current Opinion in Ophthalmology. He has been principal investigator in numerous glaucoma clinical trials. Concurrent with his research, Dr Budenz has published widely in the field of glaucoma; he has authored two textbooks, Atlas of Visual Fields and Atlas of Optical Coherence Tomography for Glaucoma, contributed numerous chapters to other books, and written or coauthored over 250 peer-reviewed journal articles. He has received Humanitarian of the Year Awards from the American Glaucoma Society and the American Academy of Ophthalmology for his work in Ghana, West Africa.

Francis Mah, MD, is specializes in advanced corneal, cataract and refractive surgery. He believes in using the latest techniques to treat each patient with compassion and respect, just as though they were members of his own family. Dr. Mah has special clinical interests in corneal diseases and infections, corneal transplant surgery (DSAEK, PKP, DALK), advanced small incision laser cataract surgery, premium intraocular lenses, and refractive surgery, such as LASIK and PRK.Dr. Mah treats corneal dystrophies, such as Fuchs’ endothelial dystrophy and anterior stromal dystrophies, as well as keratoconus and other corneal thinning disorders. In addition, he has done research and is considered an international expert on corneal infections (bacterial, viral, fungal, and parasitic).He holds leadership positions in ophthalmology academies and societies and has taught corneal surgery, LASIK and cataract surgery at academy and society meetings worldwide. A popular speaker who has been invited to delivered ophthalmic lectures on 6 continents, Dr. Mah is an esteemed educator who has disseminated his expertise through more than 200 presentations and clinical publications.Dr. Mah has been selected as a “Top Doctor” from 2013 through the present. The San Diego County Medical Society and San Diego Magazine have compiled this esteemed list of board-certified physicians who are held in the highest regard by their peers since the early 2000s.

Edward (Eddie) T. Wei (Professor Emeritus of Pharmacology) joined the University of California Berkeley faculty in 1970 and has been a research scientist ever since. Previously, he was an undergrad at Berkeley, received his Ph.D. at the University of California San Francisco Medical Center (UCSF), and post-doc’ed at Stanford. He became Professor in 1981 and retired from teaching in 2010. Wei was an NIH Merit Awardee and a Senior Fogarty Fellow at Wellcome Research Laboratories, U.K. He is an experimental scientist and considers a great fortune in his life to receive mentorship from Prof Wilhelm Feldberg FRS and Prof E. Leong Way. Wei discovered the cooling properties of icilin and gave this chemical its name. He has 150+ publications and is the Inventor of 25+ patents. In 2013, Wei created molecules called Cryosims. He is currently active in drug discovery, focusing on the therapeutic use of cooling TRPM8 agonists for sensory discomfort.

Anat Galor, M.D., is an expert on ocular surface pain and dry eye, a prevalent condition worldwide, and its relationship with neuropathic ocular pain. She is also an authority in the epidemiology and treatment of persistent pain after LASIK. Dr. Galor has evaluated the efficacy of several therapies in the treatment of neuropathic ocular pain, including gabapentinoids, periocular injections, and transcutaneous electrical stimulation. She has also focused on how ocular surface symptoms, particularly pain, affect patients’ quality of life. She has brought to light the role of nerve dysfunction in dry eye and has developed novel diagnostic and therapeutic metrics to address symptoms of dry eye and ocular pain due to nerve sensitization. She was the first to demonstrate that symptoms and signs of dry eye were often discordant, which led her to investigate whether nerve dysfunction was the missing link. Her research showed that many symptoms of dry eye, such as burning and sensitivity to wind and light, are shared with chronic pain conditions outside the eye. To test this hypothesis, she measured nerve sensitivity in both the cornea and the forearm, demonstrating that individuals with dry eye symptoms and ocular pain had increased sensitivity locally (on the cornea) and remotely (on the forearm). Based on these findings, Dr. Galor has been testing whether strategies effective in preventing and treating non-ocular pain could also be applied to ocular pain and dry eye. These include oral agents (α2δ ligands), injections, and stimulation therapy. She has published extensively in high-impact ophthalmology and pain journals, and in recognition of her contributions, Dr. Galor was named to The Ophthalmologist Power List in 2021.